Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 138

1.

Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.

Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM Jr.

J Clin Oncol. 2016 Dec 20;34(36):4338-4344. Epub 2016 Oct 28. Review.

2.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

PMID:
27911486
3.

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE; ProtecT Study Group*.

N Engl J Med. 2016 Oct 13;375(15):1425-1437. doi: 10.1056/NEJMoa1606221. Epub 2016 Sep 14.

4.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group.

N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.

5.

Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening.

Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM.

JAMA Oncol. 2016 Dec 1;2(12):1657-1660. doi: 10.1001/jamaoncol.2016.2667. No abstract available.

PMID:
27541955
6.

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J.

Eur Urol. 2016 Nov;70(5):760-766. doi: 10.1016/j.eururo.2016.03.048. Epub 2016 Apr 16.

PMID:
27090975
7.

Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J.

Clin Cancer Res. 2016 Jan 1;22(1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. Epub 2015 Aug 19.

8.

Prevalence of incidental prostate cancer: A systematic review of autopsy studies.

Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P.

Int J Cancer. 2015 Oct 1;137(7):1749-57. doi: 10.1002/ijc.29538. Epub 2015 Apr 21. Review.

9.

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ.

J Natl Cancer Inst. 2014 Dec 13;107(1):366. doi: 10.1093/jnci/dju366. Print 2015 Jan.

10.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators.

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

11.

Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.

Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Sykes J, Lockwood G, van der Kwast TH.

J Natl Cancer Inst. 2013 Jul 17;105(14):1050-8. doi: 10.1093/jnci/djt151. Epub 2013 Jul 11.

PMID:
23847245
12.

Systematic review of complications of prostate biopsy.

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y.

Eur Urol. 2013 Dec;64(6):876-92. doi: 10.1016/j.eururo.2013.05.049. Epub 2013 Jun 4. Review.

13.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

14.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

PMID:
23479454
15.

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Gulati R, Gore JL, Etzioni R.

Ann Intern Med. 2013 Feb 5;158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003.

16.

Long-term functional outcomes after treatment for localized prostate cancer.

Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF.

N Engl J Med. 2013 Jan 31;368(5):436-45. doi: 10.1056/NEJMoa1209978.

17.

Risk of suicide in men with low-risk prostate cancer.

Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, Bill-Axelson A.

Eur J Cancer. 2013 May;49(7):1588-99. doi: 10.1016/j.ejca.2012.12.018. Epub 2013 Jan 19.

18.

Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.

Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM.

Med Care. 2013 Apr;51(4):295-300. doi: 10.1097/MLR.0b013e31827da979.

19.

Radical prostatectomy versus observation for localized prostate cancer.

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group.

N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162. Erratum in: N Engl J Med. 2012 Aug 9;367(6):582.

20.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.

PMID:
22801674

Supplemental Content

Support Center